Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543983 · ClinicalTrials.gov registry record · Phase 2
Neurobiology of Suicide
A Phase 2 study of Depression and Healthy Volunteers, sponsored by National Institute of Mental Health (NIMH).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
- 1
- Study location
NCT02543983: Recruiting Phase 2 study of Depression and Healthy Volunteers, sponsored by National Institute of Mental Health (NIMH).
NCT02543983 is a Phase 2 study of Depression and Healthy Volunteers that is actively recruiting participants, run by National Institute of Mental Health (NIMH). The registered enrollment target is 325 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543983, a Phase 2 study of Depression and Healthy Volunteers, is actively recruiting participants, sponsored by National Institute of Mental Health (NIMH).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies. They hope to better understand suicide, so they can help suicidal people. Objective: To understand what happens in the brain when someone has thought about or attempted suicide. Eligibility: Group 1: Adults ages 18 70 who have thought about or attempted suicide recently Group 2: Adults ages 18 70 who have thought about or attempted suicide in the past Group 3: Adults ages 18 70 who have depression or anxiety, but have never thought about suicide Group 4: Healthy volunteers the same ages. Design: Participants will be screened in another protocol. Adults who have recently thought about or attempted suicide must be referred by a doctor. They may do up to 3 phases of this study. Groups 2, 3 and 4 will do only Phase 1 and will not get ketamine. Phase 1: 1 week in hospital. Participants will have: Physical exam. Questions about thoughts and feelings. Thinking and memory tests and simple tasks. Blood and urine tests. Two MRI scans. Participants will lie on a table that slides into a metal cylinder that takes pictures. They will have a coil over their head and earplugs and do a computer task. Sleep test. Disks and bands will be placed on the body to monitor it during sleep. Magnetic detectors on their head while they perform tasks. A wrist monitor for activity and sleep. Lumbar puncture (optional). A needle will collect fluid from the back. Shock experiments (optional). Participants will observe pictures and sounds and feel a small shock on the hand. Phase 2: 4 days in hospital. A thin plastic tube will be placed in each arm, one for blood draws, the other to get the drug ketamine once. Participants will repeat most of the Phase 1 tests. Phase 3: up to 4 more ketamine doses over 2 weeks. Participants will have follow-up calls or visits at 6 months and then maybe yearly for 5 years.
Primary Outcome
Clinical and research data and samples
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
- DEVICE Magnetic Resonance Imaging scanner, 3T
- DEVICE NeurOptics PLRTM-3000 Pupillometer
- DEVICE Experimental Anxiety Devices
- DEVICE Magnetic Resonance Imaging scanner, 7T
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2030-07-21 |
| Phase | Phase 2 |
What NCT02543983 shows while recruiting
NCT02543983 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 5 interventions - of which Ketamine Hydrochloride is the first listed.
NCT02543983 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02543983 about?
NCT02543983 is a clinical study titled "Neurobiology of Suicide". Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies. They hope to better understand suicide, so they can help suicidal people. Objective: To understand what happens in the brain wh...
What is the current status of trial NCT02543983?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2015-12-01. Estimated completion is 2030-07-21.
What conditions does trial NCT02543983 study?
This clinical trial studies the following conditions: Depression, Healthy Volunteers.
What interventions are being tested in trial NCT02543983?
The interventions under investigation include: Ketamine Hydrochloride (DRUG), Magnetic Resonance Imaging scanner, 3T (DEVICE), NeurOptics PLRTM-3000 Pupillometer (DEVICE), Experimental Anxiety Devices (DEVICE), Magnetic Resonance Imaging scanner, 7T (DEVICE).
Who is sponsoring clinical trial NCT02543983?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02543983 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02543983's enrollment target sits among peer trials
325 129th of 679 higher than 550 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Investigation to Understand and Optimize Psilocybin
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- NCT06038318 · 325 participants · NA
Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy